Administration of thiazolidinediones for neuroprotection in ischemic stroke: A pre-clinical systematic review

Journal of Neurochemistry

Volumn 115, Issue 4, 2010, Pages 845-853

  White, Amanda T ^a   Murphy, Anne N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ischemic stroke; Meta analysis; Pioglitazone; Rosiglitazone; Systematic review; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE;

BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; MEDLINE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; BRAIN ISCHEMIA; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; SPECIES SPECIFICITY; STROKE; THIAZOLIDINEDIONES;

RODENTIA;

EID: 77958610176     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06999.x     Document Type: Review

References (44)

1. Allahtavakoli M., Shabanzadeh A. P., Sadr S. S., Parviz M. and Djahanguiri B. (2006) Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. Clin. Exp. Pharmacol. Physiol. 33, 1052-1058.
2. Allahtavakoli M., Shabanzadeh A., Roohbakhsh A. and Pourshanazari A. (2007) Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin. Pharmacol. Toxicol. 101, 309-314.
3. Allahtavakoli M., Moloudi R., Arababadi M. K., Shamsizadeh A. and Javanmardi K. (2009) Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat. Brain Res. 1271, 121-127.
4. Barnett A. H. (2009) Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc. Health Risk Manag. 5, 141-51.
5. Chu K., Lee S. T., Koo J. S. et al. (2006) Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res. 1093, 208-218.
6. Craft S. (2006) Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis. Assoc. Disord. 20, 298-301.
7. Culman J., Zhao Y., Gohlke P. and Herdegen T. (2007) PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol. Sci. 28, 244-249.
8. DerSimonian R. and Laird N. (1986) Meta-analysis in clinical trials. Control Clin. Trials 7, 177-188.
9. Dormandy J. A., Charbonnel B. and Eckland D. J. et al. and PROactive investigators. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 366(9493), 1279-89.
10. DREAM Trial Investigators, Dagenais G. R., Gerstein H. C. Holman R. et al. (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31, 1007-14.
11. Fatehi-Hassanabad Z. and Tasker R. A. (2010) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation confers functional neuroprotection in global ischemia. Neurotox. Res. [Epub ahead of print. PMID: 20524105].
12. Feinstein D. L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V. and Dello Russo C. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70, 177-188.
13. Gibson C. L., Gray L. J., Bath P. M. W. and Murphy S. P. (2008) Progesterone for the treatment of experimental brain injury; a systematic review. Brain. 131, 318-328.
14. Glatz T., Stock I., Nguyen-Ngoc M., Gohlke P., Herdegen T., Culman J. and Zhao Y. (2010) Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J. Hypertens. 28, 1488-1497.
15. Graham D. J., Ouellet-Hellstrom R., MaCurdy T. E., Ali F., Sholley C., Worrall C. and Kelman J. A. (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418.
16. Hanyu H., Sato T., Kiuchi A., Sakurai H. and Iwamoto T. (2009) Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J. Am. Geriatr. Soc. 57, 177-179.
17. Howells D. W., Porritt M. J., Rewell S. S., O'Collins V., Sena E. S., Van Der Worp H. B., Traystman R. J. and Macleod M. R. (2010) Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J. Cereb. Blood Flow Metab. 30, 1412-1431.
18. Ji S., Kronenberg G., Balkaya M., Farber K., Gertz K., Kettenmann H. and Endres M. (2009) Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome. Exp. Neurol. 216, 321-328.
19. Kadoglou N. P., Iliadis F., Sailer N. et al. (2010) Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Metabolism 59, 599-607.
20. Kemp D. E., Ismail-Beigi F. and Calabrese J. R. (2009) Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am. J. Psychiatry 166, 619.
21. Lee S. R., Kim H. Y., Hong J. S., Baek W. K. and Park J. W. (2009) PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem. Biophys. Res. Commun. 380, 17-21.
22. Lin T. N., Cheung W. M., Wu J. S., Chen J. J., Lin H., Chen J. J., Liou J. Y., Shyue S. K. and Wu K. K. (2006) 15d-Prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb. Vasc. Biol. 26, 481-487.
23. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez Al. and Perez-Castillo A. (2005) Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivative through peroximsome proliferator-activated receptor gamma activation. J. Biol. Chem. 280, 21453-62.
24. Luo Y., Yin W., Signore A. P., Zhang F., Hong Z., Wang S., Graham S. H. and Chen J. (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 97, 435-448.
25. McIntyre R. S., Soczynska J. K., Woldeyohannes H. O., Lewis G. F., Leiter L. A., MacQueen G. M., Miranda A., Fulgosi D., Konarski J. Z. and Kennedy S. H. (2007) Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?. Expert Opin. Pharmacother. 8, 1615-1628.
26. Michalik L., Auwerx J., Berger J. P. et al. (2006) International Union of Pharmacology LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58, 726-741.
27. Nategh M., Shaveisi K., Shabanzadeh A. P., Sadr S. S., Parviz M. and Ghabaei M. (2010) Systemic hyperthermia masks the neuroprotective effects of MK-801, but not rosiglitazone in brain ischaemia. Basic Clin. Pharmacol. Toxicol. 107, 724-729.
28. Nissen S. E. and Wolski K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471.
29. Pereira M. P., Hurtado O., Cardenas A. et al. (2006) Rosiglitazone and 15-deoxy-Delta12, 14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J. Cereb. Blood Flow Metab. 26, 218-229.
30. Rasgon N. L., Kenna H. A., Williams K. E., Powers B., Wroolie T. and Schatzberg A. F. (2010) Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Sci. World J. 10, 321-8.
31. Schmerbach K., Schefe J. H., Krikov M., Muller S., Villringer A., Kintscher U., Unger T. and Thoene-Reineke C. (2008) Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. Brain Res. 1208, 225-233.
32. Schock S. C., Xu J., Duquette P. M., Qin Z., Lewandowski A. J., Rai P. S., Thompson C. S., Seifert E. L., Harper M. E. and Chen H. H. (2008) Rescue of neurons from ischemic injury by peroxisome proliferator-activated receptor-gamma requires a novel essential cofactor LMO4. J. Neurosci. 28, 12433-12444.
33. Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H. and Greenberg J. H. (2005) A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36, 353-359.
34. Shukla D. K., Kaiser C. C., Stebbins G. T. and Feinstein D. L. (2010) Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci. Lett. 472, 153-156.
35. Sobrado M., Pereira M. P., Ballesteros I. et al. (2009) Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J. Neurosci. 29, 3875-3884.
36. Sundararajan S., Gamboa J. L., Victor N. A., Wanderi E. W., Lust W. D. and Landreth G. E. (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130, 685-696.
37. Tureyen K., Kapadia R., Bowen K. K., Satriotomo I., Liang J., Feinstein D. L. and Vemuganti R. (2007) Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101, 41-56.
38. Victor N. A., Wanderi E. W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W. D., Landreth G. E. and Sundararajan S. (2006) Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24, 1653-1663.
39. Wang C. X., Ding X., Noor R., Pegg C., He C. and Shuaib A. (2009) Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J. Cereb. Blood Flow Metab. 29, 1683-1694.
40. Wu J. S., Cheung W. M., Tsai Y. S. et al. (2009) Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119, 1124-1134.
41. Yi J. H., Park S. W., Brooks N., Lang B. T. and Vemuganti R. (2008) PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 1244, 164-172.
42. Yki-Jarvinen H. (2004) Thiazolidinediones N. Engl. J. Med. 351, 1106-1118.
43. Zhao Y., Patzer A., Gohlke P., Herdegen T. and Culman J. (2005) The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. 22, 278-282.
44. Zhao Y., Patzer A., Herdegen T., Gohlke P. and Culman J. (2006) Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J. 20, 1162-1175.